Overview

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Status:
RECRUITING

Trial end date:
2030-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Arcus Biosciences, Inc.

Treatments:

cabozantinib